Atlas Trials

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Clinical trial NCT02993991 · WITHDRAWN

Trial details

NCT number
NCT02993991
Sponsor
University Health Network, Toronto
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Squamous Cell Carcinoma, Head And NeckSquamous Cell Carcinoma MouthResectable Squamous Cell Carcinoma of Oral Cavity
Start date
2017-10-10
Primary completion
2017-12-21
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.